Pieris Pharmaceuticals, Inc. (PIRS) financial statements (2021 and earlier)

Company profile

Business Address 255 STATE STREET
BOSTON, MA 02109
State of Incorp. NV
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments7010412873292918
Cash and cash equivalents70627538292918
Short-term investments 425335   
Receivables273160 0
Prepaid expense      0
Deferred costs 13 1 2
Other current assets      1
Other undisclosed current assets431222(2)
Total current assets:7611513590333220
Noncurrent Assets
Operating lease, right-of-use asset4 
Property, plant and equipment222054222
Long-term investments and receivables   10   
Long-term investments   10   
Other noncurrent assets331000 
Other undisclosed noncurrent assets 3    0
Total noncurrent assets:2926614222
TOTAL ASSETS:105141141104353422
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities616129632
Accounts payable2632211
Accrued liabilities11096421
Employee-related liabilities3     0
Deferred revenue13 
Debt      1
Deferred revenue and credits36372  
Deferred tax liabilities    0
Contract with customer, liability11 
Other liabilities      0
Other undisclosed current liabilities4     (0)
Total current liabilities:22274846834
Noncurrent Liabilities
Long-term debt and lease obligation16      
Operating lease, liability16 
Liabilities, other than long-term debt36475347101
Deferred revenue and credits53471  
Accounts payable and accrued liabilities     00
Deferred revenue36 
Contract with customer, liability47 
Accrued environmental loss contingencies      0
Estimated litigation liability      0
Other liabilities0 000  
Other undisclosed noncurrent liabilities 15    (0)
Total noncurrent liabilities:52635347100
Total liabilities:7490101921034
Stockholders' equity
Stockholders' equity attributable to parent, including:31514012253118
Preferred stock    0  
Common stock0000000
Additional paid in capital24322719013612911285
Accumulated other comprehensive loss(0)(2)(3)(5)(2)(1)(1)
Accumulated deficit(211)(174)(147)(120)(103)(80)(66)
Other undisclosed stockholders' equity attributable to parent      (0)
Total stockholders' equity:31514012253118
TOTAL LIABILITIES AND EQUITY:105141141104353422

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Revenue, net2711301
Gross profit:29462925635
Operating expenses(63)(73)(60)(40)(29)(17)(13)
Other undisclosed operating income      0
Operating loss:(34)(27)(31)(15)(23)(14)(7)
Nonoperating income (expense)(4)03(2)00(3)
Investment income, nonoperating  2    
Foreign currency transaction gain (loss), before tax00(0)(0)   
Debt instrument, convertible, beneficial conversion feature      2
Other nonoperating income (expense)(4)(0)2(2)000
Interest and debt expense      (3)
Other undisclosed income (loss) from continuing operations before equity method investments, income taxes12000(0) 
Loss from continuing operations before equity method investments, income taxes:(37)(25)(27)(17)(23)(14)(13)
Other undisclosed income from continuing operations before income taxes    0 3
Loss from continuing operations before income taxes:(37)(25)(27)(17)(23)(14)(10)
Income tax expense (benefit)(0) 0(1)(0)(0)0
Net loss attributable to parent:(37)(25)(27)(18)(23)(14)(10)
Other undisclosed net loss available to common stockholders, basic (3)     
Net loss available to common stockholders, diluted:(37)(28)(27)(18)(23)(14)(10)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net loss:(37)(25)(27)(18)(23)(14)(10)
Other comprehensive loss  (0)    
Comprehensive loss:(37)(25)(27)(18)(23)(14)(10)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent212(3)(0)(0)0
Comprehensive loss, net of tax, attributable to parent:(36)(24)(25)(21)(23)(14)(10)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: